A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

  • End date
    Nov 24, 2023
  • participants needed
  • sponsor
    Accendatech USA Inc.
Updated on 24 November 2021


The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.


Phase 1b: The identified RP2D of combined ACT001 with Pembrolizumab will be determined by standard 3+3 dose escalation methodology among three ACT001 dosages (200mg, 400mg and 800mg, BID) with standard Pembrolizumab dosage. Patients will be dosed approximately 2 weeks prior to surgical resection with a single dose of Pembrolizumab and ACT001. Tumor resection will be performed and a biopsy will be obtained from the resected tumor tissue to evaluate the impact of the study drugs on the TME. After recovery from surgery, patients will resume ACT001 and Pembrolizumab until tumor progression (assessed by iRANO) or an AE requiring discontinuation of study drug. The Safety Monitoring Committee (SMC) will review the data available from all evaluable patients at each dose level prior to recommending escalation to the next dose level.

Phase 2a: Using the same dosing schedule and ACT001 dosage as determined in Phase 1b. Patients will be randomized to receive either Pembrolizumab only treatment (Arm A, 10 patients) or ACT001 plus Pembrolizumab treatment (Arm B, 20 patients).

Condition Recurrent Glioblastoma Multiforme
Treatment ACT001, ACT001 + Pembrolizumab
Clinical Study IdentifierNCT05053880
SponsorAccendatech USA Inc.
Last Modified on24 November 2021


Yes No Not Sure

Inclusion Criteria

Patient has provided written informed consent
18 years old at time of screening visit
Histologically confirmed GBM at the time of diagnosis
First or second relapse by the time of consenting
Tumor progression (magnetic resonance imaging [MRI], defined by RANO) post prior treatments
Feasibility for re-surgery
Karnofsky Performance Status 70% (requires occasional assistance, but able to care for most of their needs, equivalent to < ECOG 2)
Must be 4 weeks from administration of last dose of cancer therapy (including radiation therapy or chemotherapy). The patient must have recovered from all treatment-related toxicities to less than grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Life expectancy of 3 months
Adequate organ function (absolute neutrophil count 1.5 x 109 /L, lymphocytes 0.5 x 109 /L, platelets 75 x 109 /L, hemoglobin 10 g/dl; total bilirubin 1.5 x institutional upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x ULN ( 5.0 x ULN if liver metastasis); plasma creatinine 1.5 x ULN; QTc < 450 ms (male), < 470 ms (female)
Female patients are eligible if they are of
Non-childbearing potential, defined as
Previous hysterectomy or bilateral oophorectomy
Previous bilateral tubal ligation
Post-menopausal (total cessation of menses for 1 year)
Childbearing potential with a negative serum pregnancy test at screening (within 7 days of the first investigational product administration) and uses a highly effective method contraception before study entry and throughout the study until 28 days after the last investigational product administration. Highly effective contraception (<1% failure rate per year), when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows
Vasectomized partner who is sterile prior to the female patient's enrolment and is her sole sexual partner
An intrauterine device with a documented failure rate of less than 1% per year
Double barrier contraception defined as condom with a female diaphragm
Male patients, if sexually active, must agree to use a highly effective method of contraception (< 1% failure rate per year) with their female partners from screening until 28 days following the last study drug administration
Absence of deteriorating neurological symptoms, new onset of seizures and the need for increasing doses of corticosteroids
Absence of toxicity from prior therapy (excluding alopecia) that has not resolved to Grade 1 unless otherwise specified
Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement

Exclusion Criteria

The patient has uncontrolled infection
The patient has serious diseases such as unstable angina pectoris, myocardial infarction in the past 6 months, heart failure (New York Heart Association class > II) or stroke within 6 months prior to the enrollment
A gastrointestinal absorption disorder that would limit the bioavailability of oral drugs or if patient cannot take oral drugs
Uncontrolled brain metastases or spinal cord compression. Patients who were treated with surgical resection or radiation therapy completing at least 4 weeks earlier are eligible if they are neurologically stable, not taking glucocorticoids and have a follow-up. MRI scan performed within the previous 4 weeks showing no tumor progression
Pre-existing allergy to ACT001 or related compounds
A patient has active autoimmune disease managed by systemic treatments in the past 2 years (i.e. the use of corticosteroids, immunosuppressive drugs or other disease modifying agents). Of note, a replacement therapy, e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a form of systemic treatment
A known history of, or any evidence of an active non-infectious pneumonitis
Treatment with cancer therapies such as chemotherapy or radiation therapy either currently or within 4 weeks of ACT001 dosing. An exception is focal radiation for symptomatic bone metastases, which must not be within 2 weeks of ACT001 dosing
History of treatment with immune CPB and Avastin (or other antiangiogenic or anti-vascular endothelial growth factor agents)
High dose of corticosteroids (> 4mg/day of dexamethasone or equivalent for at least 3 consecutive days) within two weeks of enrolment for GBM treatment
A patient has received other systemic immunosuppressive treatments such as mTOR inhibitor everolimus four weeks prior to registration
A patient has a diagnosis of ongoing immunodeficiency due to other diseases such as human immunodeficiency virus (HIV) infection
Unresolved toxicity from prior antitumor therapy, defined as toxicities (excluding alopecia) that have not resolved to < Grade 2 as scored using the CTCAE current version. Exceptions may be allowed for stable toxicities after discussion with the investigator and sponsor
Major surgery within 30 days of commencing first study therapy
Pregnant or breast-feeding females
A history of infection with HIV or hepatitis B or C viruses
The patient has participated in other drug clinical studies < 4 weeks prior to obtaining the informed consent
The patient is, in the opinion of the investigator, unsuitable for any other reason
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note